Citi Pharma Statistics

Total Valuation

Citi Pharma has a market cap or net worth of PKR 15.57 billion. The enterprise value is 15.71 billion.

Market Cap	15.57B
Enterprise Value	15.71B

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	Oct 17, 2024

Share Statistics

Citi Pharma has 228.46 million shares outstanding. The number of shares has decreased by -0.43% in one year.

Current Share Class	n/a
Shares Outstanding	228.46M
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	+0.48%
Owned by Insiders (%)	52.11%
Owned by Institutions (%)	12.23%
Float	101.56M

Valuation Ratios

The trailing PE ratio is 16.53.

PE Ratio	16.53
Forward PE	n/a
PS Ratio	1.20
PB Ratio	2.67
P/TBV Ratio	2.67
P/FCF Ratio	22.94
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.24, with an EV/FCF ratio of 23.15.

EV / Earnings	16.71
EV / Sales	1.21
EV / EBITDA	10.24
EV / EBIT	11.32
EV / FCF	23.15

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.25.

Current Ratio	1.36
Quick Ratio	0.61
Debt / Equity	0.25
Debt / EBITDA	0.95
Debt / FCF	2.15
Interest Coverage	5.08

Financial Efficiency

Return on equity (ROE) is 16.78% and return on invested capital (ROIC) is 11.95%.

Return on Equity (ROE)	16.78%
Return on Assets (ROA)	n/a
Return on Capital (ROIC)	11.95%
Revenue Per Employee	24.92M
Profits Per Employee	1.81M
Employee Count	519
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +192.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+192.53%
50-Day Moving Average	49.78
200-Day Moving Average	34.91
Relative Strength Index (RSI)	70.34
Average Volume (20 Days)	11,226,972

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Citi Pharma had revenue of PKR 12.93 billion and earned 940.51 million in profits. Earnings per share was 4.12.

Revenue	12.93B
Gross Profit	1.77B
Operating Income	1.39B
Pretax Income	1.45B
Net Income	940.51M
EBITDA	1.53B
EBIT	1.39B
Earnings Per Share (EPS)	4.12

Full Income Statement

Balance Sheet

The company has 1.32 billion in cash and 1.46 billion in debt, giving a net cash position of -138.35 million or -0.61 per share.

Cash & Cash Equivalents	1.32B
Total Debt	1.46B
Net Cash	-138.35M
Net Cash Per Share	-0.61
Equity (Book Value)	5.83B
Book Value Per Share	25.54
Working Capital	2.23B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.24 billion and capital expenditures -558.68 million, giving a free cash flow of 678.79 million.

Operating Cash Flow	1.24B
Capital Expenditures	-558.68M
Free Cash Flow	678.79M
FCF Per Share	2.97

Full Cash Flow Statement

Margins

Gross margin is 13.67%, with operating and profit margins of 10.73% and 7.27%.

Gross Margin	13.67%
Operating Margin	10.73%
Pretax Margin	11.25%
Profit Margin	7.27%
EBITDA Margin	11.84%
EBIT Margin	10.73%
FCF Margin	5.25%

Dividends & Yields

This stock pays an annual dividend of 3.25, which amounts to a dividend yield of 4.69%.

Dividend Per Share	3.25
Dividend Yield	4.69%
Dividend Growth (YoY)	30.00%
Years of Dividend Growth	2
Payout Ratio	60.73%
Buyback Yield	0.43%
Shareholder Yield	5.12%
Earnings Yield	6.05%
FCF Yield	4.36%

Dividend Details

Stock Splits

The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.

Last Split Date	Oct 18, 2021
Split Type	Forward
Split Ratio	1.1

Scores

Citi Pharma has an Altman Z-Score of 2.45. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.45
Piotroski F-Score	n/a